WO2004089351A3 - Methodes et moyens de traitement de troubles neurologiques progressifs - Google Patents

Methodes et moyens de traitement de troubles neurologiques progressifs Download PDF

Info

Publication number
WO2004089351A3
WO2004089351A3 PCT/GB2004/001546 GB2004001546W WO2004089351A3 WO 2004089351 A3 WO2004089351 A3 WO 2004089351A3 GB 2004001546 W GB2004001546 W GB 2004001546W WO 2004089351 A3 WO2004089351 A3 WO 2004089351A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
neurological disorders
miclobemid
tacrin
treatment
Prior art date
Application number
PCT/GB2004/001546
Other languages
English (en)
Other versions
WO2004089351A2 (fr
Inventor
Anne Jennifer Morton
Original Assignee
Univ Cambridge Tech
Anne Jennifer Morton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cambridge Tech, Anne Jennifer Morton filed Critical Univ Cambridge Tech
Publication of WO2004089351A2 publication Critical patent/WO2004089351A2/fr
Publication of WO2004089351A3 publication Critical patent/WO2004089351A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à des compositions et à des méthodes de traitement de troubles neurologiques progressifs, notamment la maladie de Huntington. L'administration d'un inhibiteur de la monoamine oxydase, notamment moclobémide, en combinaison avec un inhibiteur d'acétylcholine estérase, notamment tacrine, et éventuellement créatine, a montré améliorer les symptômes dans des systèmes de modèles murins.
PCT/GB2004/001546 2003-04-10 2004-04-07 Methodes et moyens de traitement de troubles neurologiques progressifs WO2004089351A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308382.1A GB0308382D0 (en) 2003-04-10 2003-04-10 Therapeutic methods and means
GB0308382.1 2003-04-10

Publications (2)

Publication Number Publication Date
WO2004089351A2 WO2004089351A2 (fr) 2004-10-21
WO2004089351A3 true WO2004089351A3 (fr) 2005-02-17

Family

ID=9956617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/001546 WO2004089351A2 (fr) 2003-04-10 2004-04-07 Methodes et moyens de traitement de troubles neurologiques progressifs

Country Status (2)

Country Link
GB (1) GB0308382D0 (fr)
WO (1) WO2004089351A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2089383B1 (fr) 2006-11-09 2015-09-16 Probiodrug AG Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
CA2679446C (fr) 2007-03-01 2016-05-17 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
RU2366430C2 (ru) 2007-05-23 2009-09-10 Виктор Иванович Рощин Ингибиторы моноаминооксидазы, лекарственное средство и фармацевтическая композиция
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972376A (en) * 1995-09-12 1999-10-26 Hexal, A.G. Transdermal system of tacrine/selegilin-plaster
US20020022654A1 (en) * 1997-05-21 2002-02-21 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US20020150565A1 (en) * 1999-01-08 2002-10-17 Kristoffer Hellstrand Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972376A (en) * 1995-09-12 1999-10-26 Hexal, A.G. Transdermal system of tacrine/selegilin-plaster
US20020022654A1 (en) * 1997-05-21 2002-02-21 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US20020150565A1 (en) * 1999-01-08 2002-10-17 Kristoffer Hellstrand Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRINGENBERG H C ET AL: "Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence.", NEUROREPORT. 9 NOV 2000, vol. 11, no. 16, 9 November 2000 (2000-11-09), pages 3513 - 3516, XP009036771, ISSN: 0959-4965 *
MATTHEWS T R ET AL: "NEUROPROTECTIVE EFFECTS OF CREATINE AND CYCLOCREATINE IN ANIMAL MODEL OF HUNTINGTON'S DISEASE", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 18, no. 1, 1 January 1998 (1998-01-01), pages 156 - 163, XP001094362, ISSN: 0270-6474 *
SCHNEIDER L S ET AL: "A DOUBLE-BLIND CROSSOVER PILOT STUDY OF L-DEPRENYL (SELEGILINE) COMBINED WITH CHOLINESTERASE INHIBITOR IN ALZHEIMER'S DISEASE", August 1993, AMERICAN JOURNAL OF PSYCHIATRY, AMERICAN PSYCHIATRIC ASSOCIATION, WASHINGTON, DC, US, PAGE(S) 321-323, ISSN: 0002-953X, XP001013252 *

Also Published As

Publication number Publication date
WO2004089351A2 (fr) 2004-10-21
GB0308382D0 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
WO2004078116A3 (fr) Inhibiteurs de la p 38 et leurs procedes d'utilisation
WO2006044825A3 (fr) Inhibiteurs de la kinesine mitotique et methodes d'utilisation desdits inhibiteurs
WO2008021210A3 (fr) Méthodes et compositions pour le traitement de troubles neurodégénératifs
WO2006001877A3 (fr) Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
TW200507830A (en) Bronchodilating β -agonist compositions and methods
WO2005118609A3 (fr) Petits stimulateurs de molecules de croissance neuronale
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
WO2005091853A3 (fr) Procedes et compositions pour traiter des pathologies associees a l'il-13
WO2004014352A3 (fr) Methodes de traitement de troubles dont la mediation est assuree par l'anhydrase carbonique
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2002100347A3 (fr) Promedicaments d'analogues de gaba, compositions et utilisations desdits promedicaments
WO2006024018A3 (fr) Methodes et compositions pour le traitement de la douleur nociceptive
WO2004071431A3 (fr) Composition et methode de traitement de troubles neurodegeneratifs
WO2002047668A3 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et de ciclesonide
WO2004089351A3 (fr) Methodes et moyens de traitement de troubles neurologiques progressifs
CA2416900A1 (fr) L'utilisation combine d'un inhibiteur des lipases et d'un sequestrant d'acide biliaire pharmaceutiquement acceptable pour le traitement des maladies associees avec les niveaux eleves de cholesterol dans le plasma
EP1251126A3 (fr) Derives de benzenesulfonyle a substitution fluor pour le traitment d'inflammation
WO2005099702A3 (fr) Derives de r(?)-11-hydroxyaporphines et utilisations de ces derives
WO2004105737A3 (fr) Compositions pharmaceutiques et procedes pour inhiber les adherences fibreuses au moyen de differents agents
WO2005053609A3 (fr) Methodes d'utilisation d'inhibiteurs de desacetylase nad+ dependante
WO2005014814A3 (fr) Aptameres a coiffes 5'- et 3'- et utilisations associees
WO2006058720A3 (fr) Nouveaux composes pour le traitement de troubles neurologiques
WO2006012504A3 (fr) Composes et procedes pour le traitement de thrombose
WO2005044200A3 (fr) Procedes et compositions pour traiter des pathologies associees a la mcp-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase